Pharmacological inhibition of glycogen phosphorylase (GP) lowers plasma glucose in rat models of type 2 diabetes

被引：0
|
作者：
Turnbull, A
Fraser, J
Loxham, S
Teague, J
Ellershaw, L
Roberts, D
Mayers, R
Walker, M
Evans, J
Freeman, S
Poucher, S
Carey, F
机构：
来源：
DIABETES | 2003年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A343 / A343
页数：1
相关论文
共 50 条
  • [31] Subcutaneous exendin-4 lowers both post-prandial and fasting plasma glucose in Type 2 diabetes
    Maksoud, H
    Dudley, C
    Manley, SE
    Levy, JC
    DIABETOLOGIA, 2000, 43 : A144 - A144
  • [32] The indole-2-carboxamide glycogen phosphorylase inhibitor CP-320626 lowers plasma cholesterol via lanosterol 14α-demethylase (CYP51) inhibition
    Treadway, JL
    Petras, SF
    Hoover, DJ
    Kwon, Y
    Mankowski, DC
    Mayne, JT
    Harwood, HJ
    DIABETES, 1999, 48 : A251 - A251
  • [33] Glucagon Receptor Antagonism Lowers Fasting Glucose but Not Postprandial Glucose Excursions in Patients with Type 2 Diabetes
    Haedersdal, Sofie
    Lund, Asger
    Maagensen, Henrik
    Nielsen-Hannerup, Elisabeth
    Holst, Jens Juul
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES, 2017, 66 : A532 - A532
  • [34] Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes
    Pratipanawatr, T
    Cusi, K
    Ngo, P
    Pratipanawatr, W
    Mandarino, LJ
    DeFronzo, RA
    DIABETES, 2002, 51 (02) : 462 - 468
  • [35] Estimation of the Binding Affinities of Glycogen Phosphorylase Inhibitors by Molecular Docking to Support the Treatment of Type 2 Diabetes
    Vu, T. Y.
    Le, T. -t. -h.
    Pham, T. Linh
    Vo, N. H. Hoang
    Pham, T. N. My
    Pham, M. Quan
    Phung, H. T. Thu
    PHYSICAL CHEMISTRY RESEARCH, 2024, 12 (03): : 821 - 835
  • [36] Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes
    Stravodimos, George A.
    Chetter, Ben A.
    Kyriakis, Efthimios
    Kantsadi, Anastassia L.
    Chatzileontiadou, Demetra S. M.
    Skamnaki, Vassiliki T.
    Kato, Atsushi
    Hayes, Joseph M.
    Leonidas, Demetres D.
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (04) : 384 - 403
  • [37] A novel glucagon antagonist inhibits glucagon-stimulated glucose production in human hepatocytes and lowers blood glucose in animal models of type 2 diabetes
    Van Poelje, P. D.
    Potter, S. C.
    Hou, J.
    Wu, R.
    Fujitaki, J. M.
    Reeder, D. W.
    Gomez, J.
    Linemeyer, D. L.
    Erion, M. D.
    DIABETOLOGIA, 2007, 50 : S375 - S375
  • [38] Masoprocol lowers glucose and triglyceride concentrations in mouse and rat models of non-insulin-dependent diabetes mellitus
    Reed, MJ
    Luo, J
    Meszaros, K
    Azhar, S
    Reaven, GM
    DIABETES, 1998, 47 : A102 - A102
  • [39] Acceleration of glucose-induced type 2 diabetes by chronic inhibition of nitric oxide synthesis in the rat
    Pilon, M.
    Wu, R.
    Huot-Marchand, J-E.
    deBlois, D.
    de Champlain, J.
    Couture, R.
    JOURNAL OF HYPERTENSION, 2007, 25 : S280 - S280
  • [40] Intensive Glycemic Control Lowers Plasma Visfatin Levels in Patients with Type 2 Diabetes
    Zhu, J.
    Schott, M.
    Liu, R.
    Liu, C.
    Shen, B.
    Wang, Q.
    Mao, X.
    Xu, K.
    Wu, X.
    Schinner, S.
    Papewalis, C.
    Scherbaum, W. A.
    Liu, C.
    HORMONE AND METABOLIC RESEARCH, 2008, 40 (11) : 801 - 805
12345